Short-acting β

As asthma is a chronic inflammatory disease of the airways, anti-inflammatory treatment should be positioned at the forefront of guideline-directed asthma care. However, patients tend to rely on short-acting β This nationwide, observational, cross-sectional, SABINA III study included patients (aged ≥12 years) with a documented asthma diagnosis recruited between May 2019 and January 2020 from 10 sites in the Philippines. Demographics, disease characteristics and prescribed asthma treatments, including SABA and inhaled corticosteroids (ICS) in the 12 months preceding study start, were recorded during a single visit, and transcribed onto an electronic case report form (eCRF). Patients were classified by investigator-defined asthma severity, guided by the 2017 Global Initiative for Asthma (GINA) report and practice type, either primary or pulmonary medicine specialist care. Of 245 patients analyzed, 63.3% were classified as having moderate-to-severe asthma (GINA steps 3-5), and most patients (63.3%) were enrolled by pulmonary medicine specialists. Overall, 33.1% (n=81) of patients had experienced ≥1 severe exacerbation in the previous 12 months and 18.4% (n=45) of patients had uncontrolled asthma. With respect to asthma treatments, a total of 6.5% (n=16), 40.4% (n=99), and 2.4% (n=6) of patients were prescribed SABA monotherapy, SABA in addition to maintenance therapy, and ICS, respectively, in the 12 months prior to their study visit. Most patients (n=156 [63.7%]) received prescriptions of fixed-dose combinations of ICS and long-acting β In this SABINA III Philippines study cohort, more than 10% of patients were over-prescribed SABA canisters. Additionally, prescriptions for oral or nebulized SABA, the purchase of non-prescription (OTC) SABA, and the high percentage of prescriptions for antibiotics warrant country-wide improvements in asthma care and management.

Informations de copyright

© 2023 Acta Medica Philippina.

Déclaration de conflit d'intérêts

DVD received funding and honorarium from Astra-Zeneca as principal investigator for the present study. BKBJ received funding from AstraZeneca for the present study, and for serving as a moderator during an AstraZeneca webcast. JCB received funding, including a study assistant fee, from AstraZeneca for the present study. EFHG and MJHIB were employees of AstraZeneca at the time this study was conducted. LAN, ELPS, MEVC, RZS, JFO, MHM, RSM, and JCB report no conflicts of interest.